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The type I interferon (IFN) response initiated by
detection of nucleic acids is important for antiviral
defense but is also associated with specific autoim-
mune diseases. Mutations in the human 30 repair
exonuclease 1 (Trex1) gene cause Aicardi-Goutie`res
syndrome (AGS), an IFN-associated autoimmune
disease. However, the source of the type I IFN
response and the precise mechanisms of disease in
AGS remain unknown. Here, we demonstrate that
Trex1 is an essential negative regulator of the
STING-dependent antiviral response. We used an
in vivo reporter of IFN activity in Trex1-deficient
mice to localize the initiation of disease to nonhema-
topoietic cells. These IFNs drove T cell-mediated
inflammation and an autoantibody response that
targeted abundant, tissue-restricted autoantigens.
However, B cells contributed to mortality indepen-
dently of T cell-mediated tissue damage. These find-
ings reveal a stepwise progression of autoimmune
disease in Trex1-deficient mice, with implications
for the treatment of AGS and related disorders.
INTRODUCTION
Innate immune detection of nucleic acids is an essential compo-
nent of the host response to viral infection (Barbalat et al., 2011).
In vertebrates, two families of nucleic acid receptors activate the
antiviral response. Toll-like receptors (TLRs) expressed by
sentinel innate immune cells survey phagocytosed material for
the presence of foreign nucleic acids. In contrast, intracellular
nucleic acid sensors are more broadly expressed and signal
a cell-intrinsic response to viral infection. In recent years, many
of these innate immune sensors have been identified and char-
acterized in great detail. They include TLR3, TLR7, and TLR8,
which detect various structural features of RNA, and TLR9,
which is activated by DNA. The intracellular RNA helicases
RIG-I and MDA5 detect viral RNA, whereas intracellular DNA120 Immunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc.sensing involves AIM2, DAI, IFI16, and other currently unknown
receptors (reviewed in Barbalat et al., 2011). All of these recep-
tors (with the exception of AIM2) activate expression of the
type I interferon (IFN) family of cytokines, which act to block viral
replication within infected cells and facilitate adaptive immune
responses to viral antigens (Stark et al., 1998; Stetson andMedz-
hitov, 2006b).
The IFN response triggered by nucleic acid receptors is impor-
tant for protection against infection, but it must be carefully regu-
lated to prevent inappropriate activation by endogenous DNA
and RNA. Recent studies have found that chronic activation of
these antiviral sensors can cause a number of severe autoim-
mune diseases (Banchereau and Pascual, 2006; Theofilopoulos
et al., 2005). In normal settings, this chronic activation is pre-
vented by regulating the expression and compartmentalization
of the sensors themselves (Barton and Kagan, 2009) and by
the activity of RNA and DNA nucleases that metabolize the
ligands for the receptors (Nagata et al., 2010). Thus, the imper-
fect ability of innate immune receptors to distinguish between
endogenous and foreign nucleic acids is enabled in large part
by the activities of accessory proteins.
Recent advances have established central roles for nucleic
acid-sensing TLRs and type I IFNs in a number of severe autoim-
mune diseases, including systemic lupus erythematosus (SLE)
and psoriasis (Barrat et al., 2005; Christensen et al., 2006; Lande
et al., 2007; Leadbetter et al., 2002). In addition, chronic activa-
tion of cell-intrinsic antiviral responses can also cause auto-
immunity. Specifically, we identified 30 repair exonuclease 1
(Trex1) as an essential negative regulator of the antiviral response
triggered by detection of intracellular DNA (Stetson et al., 2008).
In Trex1-deficient mice, endogenous DNA substrates accumu-
late and trigger a lethal, type I IFN-dependent autoimmune
disease. These Trex1 substrates include reverse-transcribed
DNA derived from endogenous retroelements (Stetson et al.,
2008), and Trex1 can also metabolize human immunodeficiency
virus (HIV) cDNA within infected cells (Yan et al., 2010), suggest-
ing a key role for this pathway in antiretroviral defense and an
important contribution of nucleic acids derived fromendogenous
retroelements to autoimmune disease.
Interestingly, detection of intracellular DNA can activate
two distinct antiviral responses in cells. One pathway, called
the interferon-stimulatory DNA (ISD) response (Stetson and
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four bases and triggers type I interferon production through the
adaptor protein STING (Ishikawa et al., 2009). In contrast, the
synthetic DNA polymer poly(dA:dT) can activate the STING-
dependent pathway and can also be transcribed by cellular
RNA polymerase III into a triphosphate RNA ligand that activates
the RIG-I-MAVS pathway (Ablasser et al., 2009; Chiu et al., 2009;
Ishii et al., 2006). Thus, although it is clear that Trex1 negatively
regulates the DNA-activated antiviral response, it remains
unknown whether Trex1 regulates the ISD pathway, the Pol-III
pathway, or both.
Loss-of-function mutations in the human Trex1 gene cause
Aicardi-Goutie`res syndrome (AGS), a rare and severe autoim-
mune disease that presents in infancy and mimics the features
of congenital viral infection (Crow et al., 2006). AGS is character-
ized by elevated type I IFNs, brain inflammation, and profound
psychomotor retardation, with a mortality rate approaching
35% by 15 years of age (Rice et al., 2007b). Currently, there
are no effective therapies for AGS, and the precise mechanisms
of disease remain incompletely defined.
Since the seminal identification of Trex1 mutations in AGS,
dozens of distinct mutations within the human Trex1 open
reading frame have been discovered in the context of several
disease phenotypes, including chilblain lupus and SLE (de Vries
et al., 2010; Lee-Kirsch et al., 2007; Namjou et al., 2011; Rice
et al., 2007a). Remarkably, some of thesemutations are identical
to those that cause AGS. Although the precise functional
consequences of many of these rare, lupus-associated Trex1
mutations remain unknown, the genetic association of Trex1
mutations with SLE is the strongest of any single gene identified
to date (Harley et al., 2009). Together, these studies clearly link
Trex1 and the cell-intrinsic antiviral response to DNA to a number
of IFN-associated human autoimmune disorders.
Trex1-deficient (Trex1/) mice, with a highly penetrant and
severe phenotype, are an excellent model for exploring the
mechanistic basis of disease, with direct relevance to human
AGS and SLE. These mice are particularly amenable to genetic
dissection of autoimmunity through crosses with mice deficient
in key components of innate and adaptive immunity. For
example, we found that Trex1/ mice lacking interferon regula-
tory factor 3 (IRF3), the type I IFN receptor (Ifnar1), or RAG2 are
all completely protected from autoimmune pathology and
mortality (Stetson et al., 2008). However, a number of important
questions remain: which DNA-activated antiviral response does
Trex1 regulate? Which cells initiate the disease, where, and
when? How does chronic activation of the ISD pathway lead
to lymphocyte-dependent autoimmunity? And what are the
specific contributions of lymphocytes to disease?
Here,we present a detailed characterization of the development
of disease in Trex1-deficient mice, from its earliest initiation to
organ-specific autoimmune pathology. We establish Trex1 as
a unique regulator of the STING-dependent ISD pathway. We
employ an in vivo reporter of the type I IFN response to localize
the initiation of disease and we determine how these IFNs drive
the autoreactive lymphocyte response. We show that both T cells
and B cells contribute to disease through distinct mechanisms.
Together, these findings provide new insight into the progression
of IFN-mediated autoimmunity, with implications for the human
diseases caused by chronic activation of the ISD pathway.RESULTS
Trex1-Deficient Mice Develop Specific Multiorgan
Inflammation
Trex1-deficient mice on a C57BL/6 background develop a severe
autoimmune disease, with a median life span of 10 weeks in our
colony (Morita et al., 2004; Stetson et al., 2008). Inflammatory
myocarditis is evident in all Trex1/mice, but the extent to which
other tissues are affected has not been examined. We performed
a thorough histological analysis of all major tissues and organs in
Trex1-deficient mice (Figure 1). In the heart, we found coalescing
regions of lymphohistiocytic, degenerative, and, in severe cases,
fibrosing myocarditis. This myocarditis was most prominent near
the endocardial surface. We also found that Trex1-deficient mice
reproducibly developed profound inflammation in skeletal
muscle, tongue, skin, and the glandular stomach. Similar to the
heart, the skeletal muscles and tongue had lymphohistiocytic
and degenerative to fibrosing myositis. In the haired skin of the
muzzle, therewasalsomild tomoderate lymphohistiocyticderma-
titis, perifolliculitis, and myositis. Finally, the glandular stomach
had chronic lymphoid aggregates within the mucosa and
moderate proliferative gastritis. Importantly, numerous organs
were not affected by Trex1 deficiency, including brain, colon,
small intestine,pancreas, lung, and liver (Figure1andunpublished
data). Together, these findings reveal that the autoimmune
disease in Trex1-deficient mice targets multiple, specific organs.
Trex1 Is a Specific Negative Regulator
of STING-Dependent Signaling
The multiorgan autoimmune disease in Trex1-deficient mice
requires IRF3 and type I IFNs (Stetson et al., 2008), and extranu-
clear DNA accumulates in Trex1-deficient cells (Stetson et al.,
2008;Yangetal., 2007).ThisaccumulatedDNAcouldconceivably
activate two distinct antiviral responses: the ISD-STING pathway
(Ishikawa et al., 2009) or the Pol-III-RIG-I-MAVS pathway
(Ablasser et al., 2009; Chiu et al., 2009). To determine which of
these two DNA-activated antiviral responses is regulated by
Trex1, we crossed Trex1/ mice to Mavs/ mice and to
Tmem173/ (STING-deficient) mice. We found that Trex1/
Mavs/mice developed identical autoimmune disease and suc-
cumbed with identical kinetics when compared to Trex1/ mice
(Figures 2A–2C). In contrast, Trex1/Tmem173/ mice were
completely rescued from mortality and autoimmune tissue
destruction (Figures 2A–2C). Trex1/ mice that were heterozy-
gous for Tmem173were also protected frommortality (Figure 2A),
even more so than Trex1/Irf3+/ mice (Stetson et al., 2008).
These two crosses formally establish Trex1 as a specific and
essential negative regulatorof theSTING-dependent ISDpathway
and suggest a prominent role for STING inAGSand relatedhuman
diseases. Moreover, we uncover a dramatic phenotypic conse-
quence of STING haploinsufficiency—protection from autoim-
mune disease—that may offer an evolutionary explanation for
the recently reported existence of hypomorphic TMEM173 alleles
in the human population (Jin et al., 2011).
Tracking the Origins of Type I Interferon-Mediated
Disease In Vivo
AGS in humans is strongly associated with an elevated type I IFN
response (Lebon et al., 1988), and Trex1-deficient mice lackingImmunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc. 121
Figure 1. Trex1–/– Mice Develop Specific Multiorgan Inflammation
(A) Representative hematoxylin and eosin-stained (H&E) tissue sections from Trex1 WT (top row) and Trex1–/– (bottom two rows) mice. Skeletal muscle samples
were taken from the masseter. Brain sections are from the cerebellum (top panels) and the neocortex (lower panel). Original magnifications: top two rows 103;
bottom row 203 except for neocortex, 103.
(B) Blinded analysis of indicated tissues from Trex1/ (red) or WT (blue) mice. Data are represented as histological scores from individual animals and the mean
(horizontal line) of experimental groups. Statistical analysis was performed with a two-tailed, unpaired Student’s t test. n.s. = not statistically significant (p > 0.05);
***p% 0.0005.
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tissue damage and mortality (Stetson et al., 2008). Given the
absolute requirement for STING-dependent type I IFNs in this
mouse model, we performed a simple genetic cross to track
the IFN response in vivo during disease initiation and progres-
sion. We bred Trex1+/ mice carrying an Mx1-Cre transgene
(Ku¨hn et al., 1995) to Trex1/Rag2/ mice homozygous for
the Cre-activated Rosa26-YFP reporter allele (Srinivas et al.,
2001), thereby generating Trex1+/ controls and Trex1/ mice
with an in vivo reporter of IFN activity (Figure 3A). Specifically,
IFN signaling activates expression of the IFN-inducible Mx-Cre
transgene, which then excises the LoxP-flanked ‘‘stop cassette’’
in the Rosa26-YFP reporter allele, thus turning any IFN-respon-
sive cell brightly and permanently YFP+.We examined peripheral
blood from Trex1/ and control reporter mice and found that
1 day after birth, 20% of circulating leukocytes were YFP+ in
Trex1-deficient reporter mice, compared with only 3% YFP+
cells in control mice (Figures 3A and 3B). By day 3, the frequency
of YFP+ cells in Trex1/ reporter mice increased to more than
60% and then further increased to a maximum of almost 80%
by 4 weeks of age. We observed a similar early emergence
and accumulation of YFP+ cells in Trex1/ reporter mice on
a Rag2/ background, which demonstrated that the IFN
response was independent of lymphocytes (Figure 3A, right
column). We confirmed these findings by measuring expression
of ISG15, an interferon-inducible gene, in whole embryos of plain
Trex1/ mice and controls. We found that at E14 and E17,
ISG15 expression was elevated in Trex1-deficient mice
compared to controls (Figure 3C). Thus, the IFN response that
drives disease in Trex1-deficient mice develops in utero and122 Immunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc.precedes lymphocyte-dependent inflammation and autoim-
mune tissue damage.
Based on the detection of an early systemic type I IFN
response in circulating leukocytes in Trex1-deficient reporter
mice, we examined heart tissue by immunofluorescence
microscopy to track the in situ emergence of this response
within an organ that is strongly affected by the autoimmune
disease. By day 3 after birth, we reproducibly detected (in
three out of four mice examined) a localized focus of YFP+ cells
near the endocardial surface of the apex of the heart in Trex1-
deficient reporter mice (Figure 3D). The distribution of YFP+
cells became more widespread by day 5, but remained
concentrated near the endocardial surface (Figure 3D). By
day 28, we observed a dramatic expansion of reporter fluores-
cence with the most robust signal along the entire endocardial
surface of the heart, which correlated strongly with the site of
the most extensive inflammation (Figures 3D and 1A). These
in situ data, while qualitative, reveal a number of important
insights into the origins of disease in Trex1-deficient mice.
First, the initial emergence of a detectable IFN response in
the heart occurs shortly after birth in a geographically
restricted subset of cardiac cells. Second, this IFN response
spreads rapidly but remains localized near the endocardial
surface, suggesting a process that drives the IFN response
specifically in these cells but not other, nearby cells. Finally,
the spatial overlap between the early IFN reporter signal and
the later inflammatory infiltrate suggests a causal relationship
between the site of the initial, tissue-restricted IFN response
and the site of subsequent autoimmune inflammation within
the target tissue.
Figure 2. Trex1 Is a Specific Negative Regulator of STING-Dependent Signaling
(A) Survival curves of Trex1/mice,Mavs/mice, and Trex1/Mavs/mice. TheMavs/mice were generated on a pure C57BL/6 background, so the plain
Trex1/ controls include mice generated from other contemporary crosses within this background. The Tmem173/ mice were on a mixed C57BL/6:129
background, and plain Trex1/ mice generated from intercrossing Trex1+/Tmem173+/+ mice are shown as controls.
(B) Representative H&E-stained heart tissue sections frommice of the indicated genotypes. The original magnification in the top row is 103 and in the bottom two
rows is 203.
(C) Blinded analysis of the indicated tissues of Trex1/ mice crossed to Tmem173/ and Mavs/ mice. Plain Trex1/ mice and controls are the same as in
Figure 1B and are presented for direct comparison to the other genotypes. For these and all other histological analyses presented below, statistical analysis was
performed with a two-tailed, one-way ANOVA with Tukey’s multiple comparison posttest. *p < 0.05, **p% 0.005, ***p% 0.0005.
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in Trex1-Deficient Mice
The early emergence of a type I IFN responsewithin the endocar-
dial region of Trex1-deficient hearts suggested that a tissue-
restricted IFN response might initiate the disease process. To
test this possibility, we performed a series of bone marrow
chimeras to establish tissue-specific requirements for Trex1
deficiency in the progression of autoimmune inflammation. We
used Trex1+/ or Trex1/ mice on a Rag2/ background as
recipients; Trex1/Rag2/ mice are completely rescued from
autoimmune pathology and mortality but still initiate a type I
IFN response (Figure 3A; Stetson et al., 2008), thus allowing usto examine the effects of hematopoietic reconstitution without
potentially confounding our results with preexisting inflammation
in the mutant recipients. We reconstituted irradiated Rag2/
controls or Trex1/Rag2/ mice with either wild-type (WT)
bone marrow or Ifnar1/ bone marrow. All of the Trex1/
Rag2/mice that receivedWT bonemarrow exhibited dramatic
morbidity and mortality beginning 6 weeks after reconstitution
(Figure 4A). In contrast, all of the Trex1/Rag2/mice reconsti-
tuted with Ifnar1/ bone marrow remained alive and healthy.
Rag2/ control recipients survived after reconstitution with
either WT or Ifnar1/ bone marrow. Histological analysis of
hearts by the same criteria described in Figure 1 revealed aImmunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc. 123
Figure 3. Origins of the Type I IFN Response in Trex1-Deficient Mice
(A) Representative flow cytometry plots of YFP expression in peripheral blood of Trex1/Rag2+/Rosa26-YFPR/WTMx-Cre+ or Trex1/Rag2/Rosa26-
YFPR/WTMx-Cre+ and control mice of indicated ages.
(B) Percentage of YFP+ cells from Trex1/Rag2+/Rosa26-YFPR/WTMx-Cre+ and control mice of indicated ages. Data are represented as means of percentages
(n% 7) and range.
(C) Trex1/ and control embryos of the indicated gestational age were analyzed by quantitative RT-PCR for expression of ISG15. Data are from three to six
littermates per genotype and are presented as the ratio of ISG15 to HPRT. ***p% 0.0005.
(D) Longitudinal analysis of YFP expression in heart tissue sections from Trex1/Rag2+/Rosa26-YFPR/WTMx-Cre+ and control mice of the indicated ages.
Sections were stained with anti-GFP rabbit polyclonal antibody followed by tyramide amplification (green fluorescence) and counterstained with DAPI (blue).
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mice, regardless of the genotype of the recipient or the source
of the bone marrow (Figure 4B). Within the background of
this radiation-induced inflammation, we observed a slight but
statistically insignificant increase in inflammation in the
Trex1/Rag2/ mice reconstituted with WT bone marrow
(Figure 4B).
We next createdmixed bonemarrow chimeras in which we re-
constituted Rag2/ mice or Trex1/Rag2/ mice with a 2:1
mixture of Ifnar1/ (CD45.1):WT (CD45.2) bone marrow.
Trex1/Rag2/ mice that received the mixed bone marrow
succumbed to disease with similar kinetics to those that
received onlyWTbonemarrow (Figure 4C), whereas theRag2/
recipients remained healthy. We examined the ratio of
WT:Ifnar1/ CD4 T cells in the blood, spleens, and hearts of124 Immunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc.a cohort of recipient mice euthanized 6 weeks postreconstitu-
tion. The Rag2/ control recipients maintained a ratio of
WT:Ifnar1/ cells in all three tissues that was identical to the
input ratio. In contrast, we observed a strong bias toward WT
CD4 T cells in the Trex1/Rag2/ recipients that was most
dramatic in the heart tissue (Figures 4D and 4E). This strong
WT bias was also present in CD8 T cells and in B cells, again
most prominently among the cells recovered from the heart
(data not shown). Taken together with the in situ analysis of the
IFN response in the reporter mice, these data define tissue-
specific requirements for Trex1 deficiency and type I IFNs in
the initiation and progression of disease. First, Trex1 deficiency
in nonhematopoietic cells is sufficient to drive disease, even in
the presence of a WT hematopoietic system. Second, Trex1
deficiency in hematopoietic cells, specifically lymphocytes, is
Figure 4. Nonhematopoietic Cells Initiate Disease in Trex1-Deficient
Mice
(A) Survival curves of female Trex1/Rag2/ or Rag2/ mice reconstituted
with either Ifnar1/ or WT bone marrow. Graph shows results from one out of
two independent experiments, each with five mice per group.
(B) Histological scores of hearts from Trex1/ or WT female mice recon-
stituted with either Ifnar1/ or WT bone marrow.
(C) Percent survival of Trex1/Rag2/ or Rag2/ female mice (n = 5 per
group) reconstituted with a 2:1 ratio of Ifnar1/ (CD45.1):WT (CD45.2) bone
marrow. Graph is representative of one out of two independent experiments.
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receptor signaling in hematopoietic cells is required to sense
the IFNs produced by the initiating cells, and this signaling
favors the expansion and/or recruitment of autoreactive lympho-
cytes to the target organ. This IFN-dependent lymphocyte
expansion is identical to what has been reported for T cell
responses to viral infection (Kolumam et al., 2005), suggesting
that similar mechanisms mediate both protective and autoim-
mune lymphocyte responses triggered by innate immune detec-
tion of nucleic acids.
T Cells and B Cells Drive Inflammation and Mortality
in Trex1-Deficient Mice
The IFN-dependent appearance of lymphocytes in the hearts of
Trex1-deficient recipients, together with our previous observa-
tion that lymphocytes are required for inflammation andmortality
(Stetson et al., 2008), led us to explore the individual contribu-
tions of ab T cells and B cells to the autoimmune inflammation
in Trex1/ mice. We generated Trex1/Tcra/ mice and
Trex1/Ighm/ mice and performed an extensive survival
and histological analysis of these mice and controls, compared
with plain Trex1/mice. Tcra-deficient mice develop an inflam-
matory bowel disease that is caused by a population of TCRbb+
lymphocytes that respond to environmental Helicobacter anti-
gens (Takahashi et al., 1999). Indeed, we found that the plain
Tcra/ mice in our colony suffered from increased mortality
associated with severe colitis (Figures 5A and 5E). Remarkably,
Trex1/Tcra/ mice were rescued from mortality compared
with plain Trex1/ mice, and even compared with plain Tcra/
mice (Figure 5A). Thus, ab T cells are essential for the mortality
caused by Trex1 deficiency.
We found that Trex1/Ighm/ mice that lack B cells were
dramatically rescued from mortality, with a median lifespan
that was more than seven times longer than plain Trex1/
mice (73 weeks versus 10 weeks; Figure 5A). However, after 1
year, survival of Trex1/Ighm/ mice declined steadily
compared to Ighm/ littermate controls, suggesting that
although B cells clearly play a central role in the rapid mortality
caused by Trex1 deficiency, Trex1-deficient mice lacking B cells
are not completely protected from disease.
We performed a thorough histological analysis of the affected
tissues of Trex1/ mice, Trex1/Tcra/ mice, and Trex1/
Ighm/ mice, along with Trex1 WT controls from each cross.
Remarkably, we found that ab T cells were absolutely required
for inflammation and tissue damage associated with Trex1 defi-
ciency, but B cells were largely dispensable for this inflamma-
tion. Representative heart tissue sections in Figure 5B and
histological scores in Figure 5C revealed that Trex1/Tcra/
mice were completely protected from inflammation, but
Trex1/Ighm/ mice developed extensive heart inflammation
that was statistically indistinguishable from that which devel-
oped in plain Trex1/ mice. In the other organs affected by
Trex1 deficiency, we found that Trex1/Tcra/ mice were(D) Representative flow cytometry plots of CD45.1 (Ifnar1/) and CD45.2 (WT)
expression by CD4+ cells in the indicated tissues of mixed bone marrow
recipients.
(E) The ratio of WT:Ifnar1/ CD4 T cells was calculated for the indicated
organs. We obtained identical results when examining CD8 T cells and B cells.
Immunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc. 125
Figure 5. Contributions of ab T Cells and B Cells to Autoimmunity in Trex1–/– Mice
(A) Survival curves for mice of indicated Trex1/Tcra (top) and Trex1/Ighm (bottom) genotypes. Median life spans of each Trex1/ genotype are as follows.
Trex1/, 10 weeks; Trex1/Tcra/, 56 weeks (p < 0.0001); Trex1/Ighm/, 73 weeks (p < 0.0001). Statistical analysis was performed with a Log-rank
(Mantel-Cox) test. All mice were on a C57BL/6 background.
(B) Representative H&E-stained sections of heart apex from mice of the indicated genotypes.
(C) Blinded analysis of the endocardial region in Trex1/ (red) or Trex1 WT (blue) mice of indicated Rag2, Tcra, or Ighm genotype, scored as in Figure 1B.
***p% 0.0005.
(D) Blinded analysis of tissues from Trex1/ (red) or Trex1 WT (blue) mice of indicated Tcra or Ighm genotype. *p < 0.05, **p% 0.005, ***p% 0.0005.
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Tcra/ and Trex1/Tcra/ mice had elevated inflammation
in skeletal muscle, skin, and stomach (Figure 5D). Importantly,
examination of multiple tissues allowed us to separate the
effects of Tcra deficiency from the effects of Trex1 deficiency,
most notably in the tongue and heart, where we found no
evidence of any inflammation in Trex1/Tcra/ mice (Figures
5D and 5E). Thus, we conclude that the increased mortality in
Trex1/Tcra/ mice is due to the inflammatory bowel disease
caused by Tcra deficiency, not the autoimmune disease caused
by Trex1 deficiency. In contrast, every tissue that exhibited
autoimmune pathology in plain Trex1/ mice showed similar
inflammatory infiltrates in Trex1/Ighm/ mice (Figure 5D),
demonstrating that B cells are dispensable for autoimmune
inflammation in this model.
We next tested whether differential development of fibrotic
damage could explain the dramatic rescue of Trex1/Ighm/
mice from mortality without amelioration of inflammation. We
stained heart tissue sections with picrosirius red, which detects
collagen, and found that both Trex1/ mice and Trex1/
Ighm/ mice developed fibrosis that was most extensive near
the endocardial surface, but Trex1/Tcra/ mice were com-
pletely protected from fibrosis (Figures 5F and 5G). Together,
these data demonstrate that the inflammation and fibrosis in
Trex1/ mice absolutely requires ab T cells but is largely inde-
pendent of B cells. However, B cells dramatically accelerate
mortality in Trex1/ mice, suggesting an uncoupling of T cell-
dependent inflammation from B cell-dependent processes that
may drive end-stage tissue damage.
T Cell-Dependent Autoantibody Specificities
in Trex1-Deficient Mice
We previously showed that Trex1/ mice develop a type I IFN-
dependent autoantibody response that targets heart tissue
(Stetson et al., 2008). Based on the contribution of B cells to
mortality in Trex1-deficient mice described above and the strong
genetic association in humans between rare Trex1 mutations
and SLE, we characterized the specificity of this autoantibody
response. We found that Trex1/ mice developed anti-nuclear
autoantibodies (ANA), progressive IgG deposition in kidney
glomeruli, and kidney inflammation, three hallmark features of
lupus (Figures 6A–6C; Figure S1 available online). However, we
did not find significantly elevated levels of antichromatin IgG or
anti-dsDNA autoantibodies in Trex1/ mice (Figure S1), sug-
gesting that dsDNA reactivity was not the source of the ANA
signal.
We investigated the contributions of T and B cells to these
lupus-like features by performing a comparative analysis of
kidney pathology in Trex1/Tcra/ and Trex1/Ighm/
mice. Similar to all other affected tissues in Trex1/ mice, we
found extensive interstitial inflammation in Trex1/ kidneys
that was most prominent in perivascular areas (Figures 6C and
6D). This interstitial kidney inflammation required T cells but(E) Colon sections from Trex1/ (red) or Trex1WT (blue) mice of indicated Tcra ge
of pathology.
(F) Examples of picrosirius red/fast green-stained sections of left ventricle (endo
(G) Endocardial and epicardial regions of the heart from Trex1/ (red) or Trex1W
average of the two scores was considered the total fibrosis score for each animnot B cells (Figure 6C). We also observed mild membranoproli-
ferative glomerulonephritis in Trex1-deficient kidneys, including
hypersegmentation, expanded mesangial matrix, and increased
cellularity with immune cell infiltrates (Figures 6C and 6D). Inter-
estingly, and consistent with a causal role for immune complexes
in glomerular damage, the glomeruli of Trex1/Ighm/ mice
were devoid of this inflammation (Figures 6C and 6D). Thus,
Trex1-deficient mice develop some of the cardinal features of
lupus, which providesmechanistic support for the strong genetic
association between TREX1 mutations and SLE in humans
(Lee-Kirsch et al., 2007; Namjou et al., 2011). Moreover, we
genetically separate interstitial kidney inflammation from glomer-
ulonephritis by showing that the former requires T cells and the
latter requires B cells.
We next characterized the targets of the tissue-specific auto-
antibody response by immunoprecipitating autoantigens from
heart extracts with sera from Trex1/ mice. We reproducibly
recovered a number of proteins by using Trex1/ sera but not
control sera, two of which were identical in mass to the strongest
autoantibody signals observed by protein immunoblotting of
heart extracts with Trex1/ sera (Figure 6E). We identified these
autoantigens by mass spectrometry as cardiac myosin (Myh6)
and junctophilin-2 (Jph2; Figure 6E). We confirmed the mass
spectrometry data with protein immunoblot of heart immunopre-
cipitates by using antisera specific for Myh6 and Jph2 and found
that we immunoprecipitated Myh6 and Jph2 with multiple serum
samples from Trex1/mice but not from WT littermate controls
(Figure 6F). Thus, Trex1-deficient mice reproducibly develop
autoantibodies to two abundant, heart-specific, cytosolic
proteins.
We tested the contribution of ab T cells to the heart-specific
autoantibody response in Trex1/ mice. Sera from Trex1/
mice showed strong IgG autoreactivity by protein immunoblot
with extracts from both Rag2/ and Trex1/Rag2/ hearts.
In contrast, these autoantibodies were absent in Trex1/
Tcra/ mice, demonstrating that the autoantibody response in
Trex1/ mice is T cell dependent (Figure 6G).
DISCUSSION
Type I IFNs are associated with a number of autoimmune
diseases in humans, including AGS and SLE. We describe here
a detailed characterization of the origins and progression of
the type I interferon-mediated autoimmune disease in a mouse
model of AGS. We show that STING (Tmem173) is essential for
disease in Trex1-deficient mice, thus formally establishing a
role for the STING-dependent ISD pathway in autoimmune
diseases associated with Trex1 mutations. We identify the
earliest sites of IFN production and show that these IFNs act
on hematopoietic cells to enable the autoimmune response.
We delineate the relative contributions of T and B cells to disease
and unexpectedly reveal a prominent role for B cells that is inde-
pendent of T cell-mediated inflammation and fibrotic damage.notype were graded for inflammation, mucosal changes, dysplasia, and extent
cardial region) to highlight collagen (fibrosis = red staining).
T (blue) mice of indicated Tcra or Ighm genotype were graded for fibrosis. The
al.
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Figure 6. T Cell-Dependent Autoantibody Specificities in Trex1–/– Mice
(A) Antinuclear antibodies in Trex1 WT (top) or Trex1/ (bottom) sera from age-matched mice. Serum from a MRL-lpr/lpr mouse served as a positive control.
(B) Kidney sections from Trex1 WT (top) or Trex1/ (bottom) were stained with anti-mouse IgG (green) and DAPI (blue).
(C) Interstitial kidney inflammation scores (top) and glomerulonephritis scores (bottom) for mice of the indicated genotypes. Each glomerular data point repre-
sents the average score of three individual glomeruli per animal. ***p% 0.0005.
(D) Representative images of interstitial inflammation (left) and individual glomeruli (right) from mice of the indicated genotypes. Note that the cuboidal parietal
epithelium of Bowman’s capsule is a normal finding in male mice. All images are shown at 6003 magnification.
(E) Silver stain of heart extract immunoprecipitations, using sera from WT or Trex1/mice. Immunoglobulin heavy chain (HC) and light chain (LC) are indicated.
The right panel shows a protein immunoblot (W) of heart extract blottedwith Trex1/ sera compared to the silver stain (S) of the proteins immunoprecipitatedwith
the same sera.
(F) Coimmunoprecipitation of heart extracts with sera from Trex1/ or WT mice, immunoblotted with the indicated antibodies.
(G) Heart extracts fromRag2/ (neat and 1:5 diluted) and Trex1/Rag2/mice blottedwith sera from Trex1WT, Trex1/, or Trex1/Tcra/mice of indicated
ages and detected with HRP-conjugated anti-mouse IgG.
Immunity
Tracking IFN-Dependent Autoimmunity In VivoWe identify lupus-like features as well as tissue-specific autoan-
tibody responses in Trex1/ mice. Together, these findings
provide an integrated picture of the development of autoimmune
disease caused by Trex1 deficiency and a framework for under-
standing its progression, with important implications for the
development of therapies for human AGS, which is currently
untreatable and incurable.128 Immunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc.We propose a model—based on the six genetic crosses that
ameliorate disease and our in vivo tracking of the type I IFN
response in Trex1/ mice—that links chronic activation of
the ISD pathway to lymphocyte-dependent autoimmune attack
of specific target tissues (Figure S2). First, a geographically
restricted subset of nonhematopoietic cells in the target tissue
accumulates sufficient endogenous DNA substrates to trigger
Immunity
Tracking IFN-Dependent Autoimmunity In Vivoa STING- and IRF3-dependent type I IFN response. This
response initiates in utero and is reliably detectable in specific
tissues within a day after birth, prior to the emergence of
mature lymphocytes in mice. Next, the type I IFNs produced
by the initiating cells signal to hematopoietic cells and are
required to drive a T cell-dependent inflammation and autoan-
tibody response that results in a rapidly progressing autoim-
mune destruction of the target tissue. Genetic deletion of
Tmem173, Irf3, Ifnar1, Rag2, Tcra, or Ighm rescues the mice
from mortality at distinct points along this continuum. This
model suggests a nonhematopoietic origin of the dysregulated
innate immune response that ultimately leads to autoimmunity
and reveals how therapies targeted to specific points in this
pathway might intercept disease progression. For example,
efforts to block the accumulation of Trex1 substrates or inhibit
the ISD pathway would act at the earliest phase of the autoim-
mune disease. In contrast, lymphocyte depletion would poten-
tially and temporarily ameliorate inflammation and tissue
damage, but the dysregulated innate immune response would
remain.
The application of an in vivo reporter of the IFN response in
Trex1-deficient mice reveals the initiation of this autoimmune
disease with unprecedented temporal and spatial resolution.
Perhaps most remarkably, we show that a relatively small
number of cells near the endocardial surface generates the
earliest detectable IFN response in the heart, raising the impor-
tant question of what is unique about these cells compared to
other cells in the same region. We speculate that these cells
are the first to reach a threshold level of accumulated Trex1
DNA substrates that triggers the ISD pathway, and, more
broadly, that the specific target organs affected by Trex1 defi-
ciency reflect specific cell types that trigger the early IFN
response within these tissues. We are currently exploring why
certain cells initiate early IFN production in the target organs of
Trex1/ mice, and the ability to isolate and sort these cells
based on the fluorescent reporter of type I IFN signaling will allow
for a direct comparison of these cells to their uninvolved neigh-
bors within the same tissue.
We show that both T cells and B cells contribute to the
autoimmune disease in Trex1-deficient mice, but through
distinct and genetically separable mechanisms. T cells are
necessary and sufficient for the tissue-specific autoimmune
inflammation and fibrosis, whereas B cells are not required for
either of these key disease features. However, the presence of
B cells is associated with a dramatic acceleration of morbidity
and mortality in Trex1-deficient mice. We found that membrano-
proliferative glomerulonephritis in Trex1-deficient mice uniquely
requires B cells, but we find it unlikely that this relatively mild
glomerular damage explains the dramatic difference in mortality
between plain Trex1/mice and Trex1/Ighm/mice. Impor-
tantly, our finding that B cells are dispensable for nearly all of the
autoimmune inflammation in Trex1-deficient mice may offer
a partial explanation for the disappointing results of some of
the B cell-targeted therapies that are currently being trialed in
SLE patients (Looney, 2010), especially given the strong genetic
association of rare TREX1 mutations with this disease. We
suggest that some of the inflammatory processes in a subset
of SLE patients might progress in the absence of B cells, partic-
ularly in the context of established disease.How might B cells contribute to disease in Trex1-deficient
mice? Current models suggest at least three possibilities, all
tied to the antigen specificity of the autoreactive B cells: antigen
presentation to T cells, pathogenic autoantibodies, and produc-
tion of proinflammatory cytokines. Because Trex1/Ighm/
mice still develop extensive T cell-dependent inflammation
and fibrosis, B cells cannot be the major antigen-presenting
cells in this disease. Notably, our findings in Trex1/mice differ
from those in the MRL-lpr/lpr model of murine lupus, in which B
cells are prominent antigen-presenting cells and are required
for tissue inflammation (Chan and Shlomchik, 1998). Thus,
whereas B cells are clearly important in both model systems,
the mechanisms by which they contribute to disease may be
different and determined by the nature of the genetic predispo-
sition to autoimmunity. We propose that the various (and still
poorly understood) genetic contributions to human SLE will
also reveal distinct mechanistic contributions of B cells, sug-
gesting that a pharmacogenomics approach to SLE would yield
more effective therapies to target these different disease
mechanisms.
We identified T cell-dependent autoantibodies that target
abundant, tissue-specific autoantigens, suggesting that these
autoantibodies might contribute to the rapidly progressing auto-
immune pathology in Trex1-deficient mice. To further explore
this possibility, we injected pooled sera from Trex1/ mice
into WT recipients twice in 2 days and sacrificed the recipients
5 days after the second injection to look for signs of a type II
hypersensitivity response. However, we did not find any
evidence for inflammation in WT mice injected with Trex1/
sera, suggesting that at least in this acute experimental setting,
the autoantibodies do not mediate direct toxicity in an otherwise
healthy recipient (data not shown). It remains possible, however,
that the autoantibodies directly contribute to disease in the
context of chronic, T cell-dependent inflammation. Interestingly,
the major heart autoantigens in Trex1/ mice are cytosolic
proteins, which suggests that exposure of these autoantigens
during inflammation-associated cell death in the target tissue
might be required to reveal the epitopes detected by the autor-
eactive B cells. Finally, whether B cells produce relevant proin-
flammatory cytokines in Trex1-deficient mice is currently
unknown, but can be explored in detail now that the major heart
autoantigen specificities have been identified. Thus, although
the precise mechanisms by which B cells contribute to disease
will require further study, our findings suggest that B cells may
play an important role in AGS and warrant a more thorough
search for autoantibody specificities in the human disease.
In summary, we describe the initiation and stepwise develop-
ment of IFN-dependent autoimmunity in a mouse model of
specific human autoimmune diseases. These findings provide
detailed insight into how dysregulated activation of cell-intrinsic
antiviral sensors leads to autoimmune pathology and suggest
new avenues for therapeutic intervention to intercept the disease
process.EXPERIMENTAL PROCEDURES
Mice
Rag2/, Tcra/, and Ighm/mice were purchased from Jackson Laborato-
ries. Rosa26-YFP andMx-Cre mice were generously provided by A. RudenskyImmunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc. 129
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Tracking IFN-Dependent Autoimmunity In Vivoand K. Rajewsky, respectively. Ifnar1/ CD45.2 mice were kindly provided
by M.-K. Kaja. Trex1/ mice were generously provided by D. Barnes and
T. Lindahl. Tmem173/ mice were generated as described (Ishikawa et al.,
2009) and backcrossed three times to C57BL/6 before intercrossing with
Trex1/ mice. Mavs/ mice on a C57BL/6 background were generated by
M. Loo,M.G., Jr., and colleagues (unpublished data). All mice weremaintained
and used in a specific-pathogen-free facility at the University of Washington in
accordance with the guidelines of the UW Institutional Animal Care and Use
Committee.
Pathology
Tissues were fixed in 10% neutral buffered formalin, paraffin embedded, cut
into 5 mm sections, and stained with hematoxylin and eosin or picrosirius
red. All tissues were coded to remove genotype identification and were eval-
uated for evidence of inflammation, fibrosis, and in some cases mucosal
lesions. Numerical scores were assigned based on degree of severity (0 =
normal to 5 = most severe) and extent of pathology (E1 = percent of tissue
affected in anymanner, E2 = percent of tissue affected inmost severemanner).
Unless otherwise indicated, the sum of individual scores was used to obtain
a total tissue histological score. Please see Table S1 for more specific informa-
tion about the scoring criteria for each tissue.
Bone Marrow Chimeras and Flow Cytometry
Rag2/ or Trex1/Rag2/ female mice were irradiated with 800 rads from
a cesium source and reconstituted 24 hr later with 23 106 bone marrow cells.
Mice were pretreated with and maintained on antibiotics (neomycin sulfate +
polymixin B) for 3 weeks postreconstitution. After 6–9 weeks, mice were
harvested for histology and flow cytometry analysis. Spleens and hearts
were treated with collagenase/DNase prior to surface antibody staining with
anti-CD4 (GK1.5, BD Biosciences), anti-CD45.1 (A20, eBiosciences), and
anti-CD45.2 (104, eBiosciences). Samples were acquired on a FACSCanto
(BD Biosciences) and analyzed with FlowJo software (TreeStar).
Immunofluorescence and ANA/ELISA Assays
For visualization of YFP reporter fluorescence, hearts were fixed in 4% para-
formaldehyde overnight, cryoprotected in PBS with 30% sucrose, and frozen
in Tissue-Tek OCT embedding compound (Electron Microscopy Sciences).
5 mm tissue sections were cut on a Leica CM1900 cryostat (Leica Microsys-
tems) and stained with polyclonal rabbit anti-GFP (Abcam) followed by bio-
tinylated donkey anti-rabbit F(ab0)2 (Jackson ImmunoResearch). YFP signal
was further amplified with a FITC-TSA detection kit (Perkin Elmer) according
to manufacturer’s instructions, and nuclei were counterstained with 40,6-dia-
midine-20-phenylindole dihydrochloride (DAPI; Invitrogen). For visualization
of immune complex deposition in the kidneys, 5 mm sections of fresh frozen
tissue were fixed in 100% acetone at 20C for 10 min and then stained
with anti-mouse IgG Alexa Fluor 488 (Invitrogen) and DAPI. Digital images
were acquired with a fluorescence microscope equipped with a monochrome
digital CCD camera (Orca-ER, Hamamatsu Photonics) and converted to red-
blue-green images with Adobe Photoshop CS3 software (Adobe Systems).
Detection of anti-nuclear antibodies was performed with 1:200 diluted sera
with an ANA (HEp-2) antigen substrate slide kit (MBL-BION) according to
manufacturer’s instructions. Anti-dsDNA and antichromatin ELISAs were
performed as previously described (Martin et al., 2007).
Quantitative RT-PCR
Embryos were harvested into RNAlater (QIAGEN) and homogenized the next
day with a TissueRuptor (QIAGEN) followed by RNA extraction with an RNeasy
kit (QIAGEN) according to manufacturer’s instructions. Quantitative PCR was
performed on a CFX 96 Real-Time System instrument (Biorad). The primers
used were ISG15 sense, 50-GGTGTCCGTGACTAACTCCAT-30; ISG15 anti-
sense, 50-TGGAAAGGGTAAGACCGTCCT-30; HPRT sense, 50-GTTGGATACA
GGCCAGACTTTGTTG-30; and HPRT antisense, 50-GAGGGTAGGCTGGCCT
ATAGGCT-30.
Protein Immunoblots and Coimmunoprecipitation
Heart extracts were prepared and blotted as described previously (Stetson
et al., 2008). For coimmunoprecipitations, heart extracts were precleared
with Protein G Dynabeads (Invitrogen) and incubated overnight with 1:200130 Immunity 36, 120–131, January 27, 2012 ª2012 Elsevier Inc.diluted sera from Trex1/ or control mice. Immunoprecipitated samples
were then captured by Protein G Dynabeads, washed extensively, and un-
coupled from the beads by boiling. Samples were separated by SDS-PAGE,
transferred to PVDF membranes, and incubated with anti-myosin heavy chain
or anti-junctophillin-2 (Santa Cruz Biotechnology), followed by HRP-conju-
gated secondary antibodies.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and one table and can be found
with this article online at doi:10.1016/j.immuni.2011.11.018.
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